alexa New Inhibitors Against Herpes Viruses
ISSN 2155-6113

Journal of AIDS & Clinical Research
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

2nd International Conference on HIV/AIDS, STDs, & STIs
October 27-29, 2014 Embassy Suites Las Vegas, USA

Arezki Azzi, M?lanie Martin, Sheng-Xiang Lin and Guy Boivin
Accepted Abstracts: J AIDS Clin Res
DOI: 10.4172/2155-6113.S1.009
Tridimensional protein modeling and virtual drug screening were performed to identify new inhibitors of Herpes virus DNA polymerase, a key enzyme in the viral replication cycle. Twelve potential inhibitors were identified, purchased and evaluated by plaque assays. Two compounds (Nos 2 and 9) were particularly active against HSV-1, HSV-2 and varicella-zoster virus (VZV) and one compound (No 3) inhibited more specifically human Cytomegalovirus (HCMV). These compounds exhibited activity against wild-type viruses and strains resistant to current antiviral agents, i.e. nucleoside and pyrophosphate analogues, with IC50 values between 3 and 10 μM. Furthermore, compounds 2 and 3 had good cellular permeability and metabolic stability as determined by parallel artificial membrane permeability assay (PAMPA) and microsomal stability assay, respectively. Derivatives of these compounds were also synthesized to evaluate their activity against representative strains of HSV-1, HSV-2, VZV and HCMV as well as their toxicity on different cell lines. One fluoro derivative of compound 2 (No 20) retained excellent activity against HSV-1, HSV-2 and VZV with a therapeutic index near 10 in Vero cells. In conclusion, we discovered a new class of non-nucleosidic Herpes virus inhibitors with in vitro activity against drug-resistant clinical isolates that warrant further pre-clinical studies.
image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version